NFL Biosciences: stock rises after positive results

(CercleFinance.com) - NFL Biosciences' share price climbed on the Paris Bourse on Tuesday, following the biopharmaceutical company's publication of positive results for its proposed treatment for tobacco addiction.


Around 12:00 pm, the share price jumped 9%, making it one of the strongest gains on the Paris market.

This morning, the company specializing in botanical medicines for the treatment of addiction published the positive results of a complementary program confirming the excellent safety profile of NFL-101, its candidate drug for the treatment of tobacco addiction.

The toxicity study, which evaluated daily subcutaneous administration of increasing doses of NFL-101 in rats for 14 days, showed that the maximum cumulative dose tested - 630 times higher than the cumulative dose evaluated in humans - did not induce any signs of systemic or local toxicity.

From NFL's point of view, the complete absence of adverse effects and signs of toxicity at the doses evaluated in this study suggests that NFL-101's actual safety threshold could be even higher.

These results support the safety profile of NFL-101, which is Champix's main flaw", commented analysts at Allinvest Securities.

Pfizer's Champix drug, which is supposed to help smoking cessation, is suspected of causing suicidal ideation, which led to its delisting in France.

This toxicity study reinforces the clinical case for NFL-101 and strengthens the group's argument for negotiating a licensing agreement for phase III development", adds the stock exchange company.

NFL says it is currently pursuing discussions with the regulatory authorities in order to establish the best possible development plan with a view to bringing NFL-101 to market.

The company also says it is working on the industrial development of the product in order to produce batches suitable for use in phase 3.

Copyright (c) 2025 CercleFinance.com. All rights reserved.